Challenges and Opportunity With MRI

Opinion
Video

This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.

Ahmed Obeidat, MD, PhD, recounts the difficulties with MRI as a main biomarker for MS and shares strategies for optimal use of the technology.

Mark Freedman, MD, MSc, questions Ahmed Obeidat, MD, PhD, on his satisfaction with MRI as the primary biomarker for multiple sclerosis (MS) and how variability, cost, and limitations in conventional MRI impact clinical monitoring. Ahmed Obeidat, MD, PhD, acknowledges the challenges and highlights the reduced frequency of ordering MRIs, especially for stable patients on highly effective therapies.

Expressing dissatisfaction with the limited utility of conventional MRI for monitoring, Ahmed Obeidat, MD, PhD, emphasizes the importance of advanced MRI techniques, mentioning volume metrics, central vein sign, and normally appearing white matter. He discusses the need for quantitative biomarkers, expressing interest in fluid biomarkers for their potential in providing additional information beyond conventional MRIs.

Ahmed Obeidat, MD, PhD, advocates for combining imaging and fluid biomarkers in clinical practice for a more comprehensive understanding of the disease. He underscores the value of a quantitative biomarker, stating it could enhance patient comprehension and aid in assessing disease control.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Related Videos
Patricia K. Coyle, MD
Video 2 - 5 KOLs are featured in "Natural History of Spinal Muscular Atrophy"
Video 1 - 5 KOLs are featured in "Clinical Features and Phenotypes of Spinal Muscular Atrophy"
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
Kathy Zackowski, PhD, OTR
A panel of 3 experts on Alzheimer's disease
A panel of 3 experts on Alzheimer's disease
© 2024 MJH Life Sciences

All rights reserved.